SCYNEXIS (SCYX) 10-Q 9 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 15, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	SCYNEXIS INC
Entity Central Index Key	1,178,253
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		13,906,828

Unaudited Condensed Balance She

Unaudited Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 38,016	$ 46,985
Prepaid expenses and other current assets	1,905	1,452
Total current assets	39,921	48,437
Other assets	429	419
Deferred offering costs	331	417
Total assets	40,681	49,273
Current liabilities:
Accounts payable	1,380	619
Accrued expenses	2,574	3,149
Accrued severance and retention costs, current portion	830	2,639
Deferred revenue, current portion	257	257
Total current liabilities	5,041	6,664
Deferred revenue, non-current	571	635
Deferred rent	25	25
Total liabilities	$ 5,637	$ 7,324
Commitments and contingencies
Stockholders’ equity:
Preferred stock	$ 0	$ 0
Common stock	14	14
Additional paid-in capital	192,348	192,069
Accumulated deficit	(157,318)	(150,134)
Total stockholders’ equity	35,044	41,949
Total liabilities and stockholders’ equity	$ 40,681	$ 49,273

Unaudited Condensed Balance Sh3

Unaudited Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	125,000,000	125,000,000
Common stock, shares issued (in shares)	13,906,828	13,905,599
Common stock, shares outstanding (in shares)	13,906,828	13,905,599
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000

Unaudited Condensed Statements

Unaudited Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenue	$ 64	$ 65
Operating expenses:
Research and development, net	4,743	3,787
Selling, general and administrative	2,533	2,210
Total operating expenses	7,276	5,997
Loss from operations	(7,212)	(5,932)
Other (income) expense:
Interest income	(28)	(1)
Total other income	(28)	(1)
Loss from continuing operations before tax	(7,184)	(5,931)
Discontinued operations:
Loss from discontinued operations	0	(453)
Net loss	$ (7,184)	$ (6,384)
Income (loss) per share attributable to common stockholders - basic
Continuing operations, per basic share (USD per share)	$ (0.52)	$ (0.70)
Discontinued operations, per basic share (USD per share)	0	(0.05)
Net loss per share - basic (USD per share)	$ (0.52)	$ (0.75)
Weighted average common shares outstanding:
Weighted average common shares outstanding, basic and diluted (in shares)	13,905,613	8,516,467

Unaudited Condensed Statements5

Unaudited Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net loss	$ (7,184)	$ (6,384)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	3	323
Stock-based compensation expense	274	296
Write off of deferred offering costs	111	0
Changes in deferred rent	0	(57)
Changes in operating assets and liabilities:
Accounts receivable and unbilled services	0	448
Prepaid expenses, other assets, and deferred costs	(477)	(160)
Accounts payable and accrued expenses	186	1,052
Accrued severance and retention cost obligations	(1,809)	0
Deferred revenue	(64)	(65)
Net cash used in operating activities	(8,960)	(4,547)
Cash flows from investing activities:
Purchases of property and equipment	(14)	(171)
Net cash used in investing activities	(14)	(171)
Cash flows from financing activities:
Proceeds from employee stock purchase plan issuance	5	95
Net cash provided by financing activities	5	95
Net decrease in cash and cash equivalents	(8,969)	(4,623)
Cash and cash equivalents, beginning of period	46,985	32,243
Cash and cash equivalents, end of period	38,016	27,620
Supplemental cash flow information:
Cash received for interest	28	0
Noncash financing and investing activities:
Deferred offering costs included in accounts payable and accrued expenses	25	257
Equipment purchases in accounts payable and accrued expenses	$ 0	$ 25

Description of Business and Bas

Description of Business and Basis of Preparation	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Preparation	Description of Business and Basis of Preparation Organization SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999 . SCYNEXIS is a pharmaceutical company, headquartered in Jersey City, New Jersey, committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans. The Company has incurred losses and negative cash flows from operations since its initial public offering ("IPO") in May 2014 and expects to continue to incur losses. The Company's liquidity over the next 12 months could be materially affected by, among other things: its ability to raise capital through equity offerings, debt financings, other non-dilutive third-party funding (e.g., grants), strategic alliances and licensing or collaboration arrangements; key SCY-078 development and regulatory events; costs related to its development of SCY-078; and other factors. Shelf Registration Filing On October 30, 2015, the Company filed a shelf registration statement on Form S-3 with the SEC which was declared effective on November 16, 2015. The registration statement contained two prospectuses: • a base prospectus which covers the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $150,000 of the Company's common stock, preferred stock, debt securities and warrants, including common stock or preferred stock issuable upon conversion of debt securities, common stock issuable upon conversion of preferred stock, or common stock, preferred stock or debt securities issuable upon the exercise of warrants (the "Shelf Registration"), and • a prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $40,000 of the Company's common stock that may be issued and sold under a sales agreement with Cowen and Company, LLC ("Cowen"). On April 10, 2016, the Company terminated the sales agreement with Cowen and on April 11, 2016, entered into a Controlled Equity Offering Sales Agreement SM (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”). Pursuant to the Sales Agreement, the Company may sell from time to time, at its option, up to an aggregate of $40,000 of the Company’s common stock, through Cantor, as sales agent (the “ATM Offering”). Pursuant to the Sales Agreement, sales of the common stock, if any, will be made under the Company’s previously filed and currently effective registration statement on Form S-3 (File No. 333-207705) . See Note 12 for further details. The common stock that may be offered, issued and sold by the Company under the Sales Agreement is included in the $150,000 of securities that may be offered, issued and sold by the Company under the base prospectus. Upon termination of the sales agreement with Cantor, any portion of the $40,000 included in the Sales Agreement that is not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus and a corresponding prospectus supplement, and if no shares are sold under the sales agreement, the full $150,000 of securities may be sold in other offerings pursuant to the base prospectus. Unaudited Interim Financial Information The accompanying unaudited financial statements and notes have been prepared in accordance with accounting principles generally accepted in the United States, or US GAAP, as contained in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (the “Codification” or “ASC”) for interim financial information. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the results of operations, financial position, and cash flows. The results of operations for the three months ended March 31, 2016 , are not necessarily indicative of the results for the full year or the results for any future periods. These interim financial statements should be read in conjunction with the financial statements and notes set forth in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC") on March 7, 2016. Discontinued Operations As described in Note 11, the Company met the relevant criteria for reporting the Company's contract research and development services business (the "Services Business") in discontinued operations in the second quarter of 2015. The accompanying unaudited interim financial statements present the Services Business as discontinued operations for the three months ended March 31, 2016, and 2015, pursuant to FASB Topic 205-20, Presentation of Financial Statements--Discontinued Operations . Use of Estimates The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Significant estimates include: the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and estimates utilized in recognizing stock-based compensation for options granted to employees and nonemployees.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Cash and Cash Equivalents The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents. Concentration of Credit Risk Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit with a bank, which exceeds the FDIC insurance limits, as well as accounts receivable. Ongoing credit evaluations of the bank and customers' financial condition and independent ratings are reviewed by the Company. Collateralization of deposits has not been required. Other Assets Other assets consist primarily of the refundable long-term deposit on the leased building facility and the restricted cash posted as collateral for the Company's corporate credit card program. Deferred Offering Costs Deferred offering costs are expenses directly related to the Form S-3 filed with the SEC on October 30, 2015 and declared effective on November 16, 2015 (the "Shelf Registration"). These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized, including fees incurred by the independent registered public accounting firm directly related to the Shelf Registration. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis in the event the Company completes an offering under the Shelf Registration, with any remaining deferred offering costs charged to the results of operations at the end of the three-year life of the Shelf Registration. During the three months ended March 31, 2016, the Company expensed $111 of deferred offering costs associated with the Shelf Registration as a result of the termination of the "at the market" ("ATM") offering program entered into with Cowen and Company, LLC (“Cowen”) on November 11, 2015. See Note 12 for further details. Comprehensive Loss The Company has no items of comprehensive income or loss other than net loss. Revenue Recognition and Deferred Revenue The Company has entered into collaboration arrangements in exchange for non-refundable upfront payments and consideration as services are performed. These arrangements include multiple elements, such as the sale of licenses and the provision of services. Under these arrangements, the Company also is entitled to receive development milestone payments and royalties in the form of a designated percentage of product sales. The Company classifies non-refundable upfront payments, milestone payments and royalties received under collaboration and licensing agreements as revenues within its statements of operations because the Company views such activities as being central to its business operations. Revenue is recognized when all of the following conditions are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) fees are fixed or determinable, and (iv) collection of fees is reasonably assured. When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in ASC subtopic 605-25, Multiple-Element Arrangements . If the Company determines that an arrangement includes multiple elements, it determines whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting. An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s arrangements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered. Non-refundable upfront license fees are recorded as deferred revenue and recognized into revenue on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, the Company recognizes non-refundable upfront fees into revenue through the date the deliverable is satisfied. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. In arrangements that include license rights and other non-contingent deliverables, such as participation in a steering committee, these deliverables do not have standalone value because the non-contingent deliverables are dependent on the license rights. That is, the non-contingent deliverables would not have value without the license rights, and only the Company can perform the related services. Upfront license rights and non-contingent deliverables, such as participation in a steering committee, do not have standalone value as they are not sold separately and they cannot be resold. In addition, when non-contingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate earnings process. As such, the Company accounts for the license and the non-contingent deliverables as a single combined unit of accounting. In such instances, the license revenue in the form of non-refundable upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes contingent event-based payments under license agreements when the payments are received. The Company has not received any royalty payments to date. The Company will recognize a milestone payment when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it: 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement. Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets. The Company’s deferred revenue includes non-refundable upfront payments received under certain licensing and collaboration arrangements that contain substantive performance obligations that the Company is providing over respective defined service or estimated relationship periods. Such non-refundable upfront payments are recognized over these defined service or estimated relationship periods. The Company received a non-refundable upfront payment of $1,500 from R-Pharm in August 2013 which is being recognized over a period of 70 months. The Company recognized revenue in continuing operations from this upfront payment of $64 and $65 for the three months ended March 31, 2016 and 2015, respectively. Collaboration Arrangements The Company assesses its contractual arrangements, and presents costs incurred and payments received under contractual arrangements, in accordance with ASC 808, Collaborative Arrangements ("Topic 808"), when the Company determines that the contractual arrangement includes a joint operating activity, has active participation by both parties, and both parties are subject to significant risks and rewards under the arrangement. When reimbursement payments are due to the Company under a collaborative arrangement within the scope of Topic 808, the Company determines the appropriate classification for each specific reimbursement payment in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement. The Company's August 2013 development, license, and supply agreement with R-Pharm, CJSC (“R-Pharm”), combined with the supplemental arrangement in November 2014, is a collaborative arrangement pursuant to Topic 808 and the Company’s previously described accounting policy. The reimbursements due from R-Pharm for specified research and development costs incurred by the Company are classified as a reduction to research and development expense in the accompanying statements of operations. The reimbursements due to the Company are recorded as a reduction of expense when (i) the reimbursable expenses have been incurred by the Company, (ii) persuasive evidence of a cost reimbursement arrangement exists, (iii) reimbursable costs are fixed or determinable, and (iv) the collection of the reimbursement payment is reasonably assured. The Company recorded receivables for unpaid reimbursement amounts due from R-Pharm of $648 and $430 as of March 31, 2016 and December 31, 2015, respectively, which are presented in prepaid expenses and other current assets in the accompanying balance sheets. Research and Development Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance. The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting SCY-078 clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel. Reimbursements of certain research and development costs by parties under collaborative arrangements have been recorded as a reduction of research and development expense presented within the statement of operations. Such reimbursements were recognized under the collaboration arrangement with R-Pharm during the three months ended March 31, 2016 . Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the three months ended March 31, 2016 and 2015, is presented as follows: Three months ended March 31, 2016 2015 Research and development expense, gross $ 4,962 $ 3,981 Less: Reimbursement of research and development expense 219 194 Research and development expense, net of reimbursements $ 4,743 $ 3,787 Patent Expenses Costs related to filing and pursuing patent applications, as well as costs related to maintaining the Company's existing patent portfolio, are recorded as expense as incurred since recoverability of such expenditures is uncertain. Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability.The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows: • Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; • Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and • Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. Income Taxes The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions. Certain modifications made to an outstanding incentive stock option award at any time after the initial grant dates which are considered to be “material modifications”, as defined within the Internal Revenue Code, may result in the affected award being recharacterized as a non-statutory stock option. The effects of any recharacterization modification for purposes of income tax accounting are recognized on a prospective basis. Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date. The Company values equity instruments and stock options granted to employees and non-employee directors using the Black-Scholes valuation model. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods. Basic and Diluted Net Loss per Share of Common Stock The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share ("Topic 260”). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive. Three Months Ended March 31, 2016 2015 Warrants to purchase Series C-1 Preferred 14,033 14,033 Stock options 1,450,453 575,416 Effect of Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606, or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In applying the new revenue recognition model to contracts with customers, an entity: (1) identifies the contract(s) with a customer; (2) identifies the performance obligations in the contract(s); (3) determines the transaction price; (4) allocates the transaction price to the performance obligations in the contract(s); and (5) recognizes revenue when (or as) the entity satisfies a performance obligation. The accounting standards update applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification. The accounting standards update also requires significantly expanded quantitative and qualitative disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the Company’s financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is not early adopting ASU 2014-15. The Company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the Company’s financial statements, and the actual impact will be dependent upon the Company’s liquidity and the nature or significance of future events or conditions that exist upon adopting the updated standard. In February 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-02, Leases , or ASU 2016-02. The new guidance requires lessees to recognize the assets and liabilities arising from leases on the balance sheet. For public companies, ASU 2016-02 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2018, and early adoption is permitted. The Company is currently evaluating the impact that the implementation of ASU 2016-02 will have on the Company’s financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation , or ASU 2016-09. The new guidance is an update to ASC 718 and simplifies several aspects of the accounting for share-based transactions. For public companies, ASU 2016-09 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016. The Company is currently evaluating the impact that the implementation of ASU 2016-09 will have on the Company’s financial statements. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers , or ASU 2016-10. The new guidance is an update to ASC 606 and provides clarity on: identifying performance obligations and licensing implementation. For public companies, ASU 2016-10 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016. The Company is currently evaluating the impact that the implementation of ASU 2016-10 will have on the Company’s financial statements.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets March 31, 2016 December 31, 2015 Prepaid SCY-078 development services $ 513 $ 108 Prepaid insurance 99 285 Other prepaid expenses 145 91 Other receivable due from R-Pharm 648 430 Escrow receivable due from Accuratus (Note 11) 500 500 Other current assets — 38 Total prepaid expenses and other current assets $ 1,905 $ 1,452

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2016
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses March 31, 2016 December 31, 2015 Accrued research and development expenses $ 1,950 $ 1,903 Accrued employee bonus compensation 215 776 Employee withholdings 25 42 Other accrued expenses 384 428 Total accrued expenses $ 2,574 $ 3,149

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases The Company leases its headquarters facilities under a long-term non-cancelable operating lease. On July 13, 2015, the Company entered into a sublease (the "Sublease") that became effective July 22, 2015, to sublet certain premises consisting of 10,141 square feet of space (the "Subleased Premises") located at 101 Hudson Street, Jersey City, New Jersey from Optimer Pharmaceuticals, Inc. The term of the Sublease commenced on August 1, 2015 (the "Commencement Date") and is scheduled to expire on July 30, 2018. No base rent was due under the Sublease until one month after the Commencement Date. Under the Sublease, the Company is obligated to pay monthly base rent of approximately $25 per month, which amount increases by 3% annually on each anniversary of the Commencement Date. In addition, the Company was required to fund a security deposit with the sublandlord in the amount of $74 . Rent expense was approximately $74 for the three months ended March 31, 2016. Future minimum lease payments for all operating leases as of March 31, 2016 are as follows: March 31, 2016 to December 31, 2016 $ 224 2017 307 2018 182 2019 — 2020 — Thereafter — Total $ 713 License Arrangement with Potential Future Expenditures As of March 31, 2016 , the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, that involves potential future expenditures. Under the license arrangement, the Company exclusively licensed from Merck its rights to SCY-078 in the field of human health. SCY-078 is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck is eligible to receive milestone payments from the Company that could total $19,000 upon occurrence of specific events, including initiation of a phase 3 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of SCY-078. The aggregate royalty percentages are mid- to high-single digits. In December 2014, the Company and Merck entered into an amendment to the license agreement that deferred the remittance of a milestone payment due to Merck, such that no amount would be due upon initiation of the first phase 2 clinical trial of a product containing the SCY-078 compound (the "Deferred Milestone"). The amendment also increased, in an amount equal to the Deferred Milestone, the milestone payment that would be due upon initiation of the first Phase 3 clinical trial of a product containing the SCY-078 compound. Except as described above, all other terms and provisions of the license agreement remain in full force and effect. The Company has two additional licensing agreements for other compounds that could require it to make payments of up to $2,300 upon achievement of certain milestones by the Company. Clinical Development Arrangements The Company has entered into, and expects to continue to enter into, contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice. Commitment Services Agreement In connection with the sale of the Services Business, the Company and Accuratus Lab Services, Inc. ("Accuratus") entered into a Commitment to Services Agreement (the "Services Agreement") pursuant to which Accuratus will provide the Company with certain contract research and development services. The material terms of the Services Agreement are described in Note 11. Compensatory Arrangements with Former Employees and Officers The Company has entered into certain compensatory arrangements and commitments with former employees and officers, the material terms of which are described in Note 10.

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Common Stock	Common Stock Authorized, Issued, and Outstanding Common Shares The Company’s common stock has a par value of $0.001 per share and consists of 125,000,000 authorized shares as of March 31, 2016 , and December 31, 2015 ; 13,906,828 and 13,905,599 shares were issued and outstanding at March 31, 2016 , and December 31, 2015 , respectively. The following table summarizes common stock share activity for the three months ended March 31, 2016 : Shares of Common Stock Additional Paid-in Capital Accumulated Deficit Total Stockholders' Equity Balance, December 31, 2015 13,905,599 $ 14 $ 192,069 $ (150,134 ) $ 41,949 Net loss — — — (7,184 ) (7,184 ) Stock-based compensation expense — — 274 — 274 Common stock issued through employee stock purchase plan 1,229 — 5 — 5 Balance, March 31, 2016 13,906,828 $ 14 $ 192,348 $ (157,318 ) $ 35,044 Shares Reserved for Future Issuance The Company had reserved shares of common stock for future issuance as follows: March 31, December 31, Outstanding stock options 1,450,453 1,379,727 Outstanding Series C-1 Preferred warrants 14,033 14,033 For possible future issuance under 2014 Equity Incentive Plan (Note 8) 1,037,822 552,415 For possible future issuance under Employee Stock Purchase Plan (Note 8) 78,465 50,283 For possible future issuance under 2015 Inducement Plan (Note 8) 165,000 165,000 Total common shares reserved for future issuance 2,745,773 2,161,458 Warrants Associated with Convertible Preferred Stock Issuances In July 2006, the Company issued warrants to purchase 196,923 shares of Series C-1 Preferred Stock, which converted into the right to purchase 14,033 shares of common stock in connection with our IPO, however, we refer to these warrants as our Series C-1 Preferred warrants. The Series C-1 Preferred warrants were issued in conjunction with a loan financing agreement with an original exercise price of $3.25 per share of Series C-1 Preferred, which converted into an exercise price of $45.61 per share of common stock in connection with our IPO. These warrants remain outstanding as of March 31, 2016 and will expire on May 7, 2019, which is the five year anniversary of the Company's IPO. The fair value at the date of grant for these instruments was $459 , which was recorded as a debt discount. The debt discount related to these warrants was fully amortized as of December 31, 2010. The Company determined that the warrants should be recorded as a derivative liability and stated at fair value at each reporting period. As of March 31, 2016 and December 31, 2015, the fair value of the warrant derivative liability was zero.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company applies intraperiod tax allocation guidance pursuant to Topic 740 to allocate income tax (expense) benefit between pre-tax income (loss) from continuing operations and discontinued operations. For periods in which the Company reports pre-tax income from discontinued operations for financial reporting purposes and pre-tax loss from continuing operations, the Company presents income from discontinued operations net of income tax expense attributable to its discontinued operations using the estimated annual effective tax rate of the Services Business. The Company also recognizes a corresponding income tax benefit on its loss from continuing operations for the same affected period. After applying the intraperiod tax allocation policy described above, the Company did not record a federal or state income tax expense or benefit for the three months ended March 31, 2016 .

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	Stock-based Compensation 2009 Stock Option Plan The Company had a share-based compensation plan (the “2009 Stock Option Plan”) under which the Company granted options to purchase shares of common stock to employees, directors, and consultants as either incentive stock options or nonqualified stock options. Incentive stock options could be granted with exercise prices not less than 100% to 110% of the fair market value of the common stock. Options granted under the plan generally vest over three to four years and expire in 10 years from the date of grant. 2014 Equity Incentive Plan In February 2014, the Company’s board of directors adopted the 2014 Equity Incentive Plan, or the 2014 Plan, which was subsequently ratified by its stockholders and became effective on May 2, 2014 (the “Effective Date”). The 2014 Plan, as amended on June 18, 2014 and February 25, 2015, is the successor to and continuation of the 2009 Stock Option Plan. As of the Effective Date, no additional awards will be granted under the 2009 Stock Option Plan, but all stock awards granted under the 2009 Stock Option Plan prior to the Effective Date will remain subject to the terms of the 2009 Stock Option Plan. All awards granted on and after the Effective Date will be subject to the terms of the 2014 Plan. The 2014 Plan provides for the grant of the following awards: (i) incentive stock options, (ii) nonstatutory stock options, (iii) stock appreciation rights, (iv) restricted stock awards, (v) restricted stock unit awards, and (vi) other stock awards. Employees, directors, and consultants are eligible to receive awards. Under the 2014 Plan, after giving effect to the increases to the share reserve approved by the Company’s stockholders in September 2014, and June 2015, but excluding the automatic increases discussed below, the aggregate number of shares of common stock that could be issued from and after the Effective Date (the “share reserve”) could not exceed the sum of (i) 1,122,731 new shares, (ii) the shares that represented the 2009 Stock Option Plan’s available reserve on the Effective Date, and (iii) any returning shares from the 2009 Stock Option Plan. Under the 2014 Plan, the share reserve will automatically increase on January 1 st of each year, for a period of not more than 10 years, commencing on January 1, 2015, and ending on January 1, 2024, in an amount equal to 4.0% of the total number of shares of capital stock outstanding on December 31 st of the preceding calendar year. The board of directors may act prior to January 1 st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. Pursuant to the terms of the 2014 Plan, (a) on January 1, 2015, the Company automatically added 340,484 shares to the total number of shares of common stock available for future issuance under the 2014 Plan, and (b) on January 1, 2016, the Company automatically added 556,223 shares to the total number of shares of common stock available for future issuance under the 2014 Plan. Stock Option Grants During the three months ended March 31, 2016, the Company granted options to purchase 86,795 shares of common stock. As of March 31, 2016 , there were 1,037,822 shares of common stock available for future issuance under the 2014 Plan. 2015 Inducement Plan On March 26, 2015, the Company's board of directors adopted the 2015 Inducement Plan, or the 2015 Plan. The 2015 Plan has a share reserve covering 450,000 shares of common stock. During the quarter ended March 31, 2016, there were no grants of the Company's common stock under the 2015 Inducement Plan. As of March 31, 2016 , there were 165,000 shares of common stock available for future issuance under the 2015 Plan. 2014 Employee Stock Purchase Plan In February 2014, the Company’s board of directors adopted the 2014 Employee Stock Purchase Plan (“ESPP”), which was subsequently ratified by the Company’s stockholders and became effective on May 2, 2014 . The purpose of the ESPP is to provide means by which eligible employees of the Company and of certain designated related corporations may be given an opportunity to purchase shares of the Company’s common stock, and to seek and retain services of new and existing employees and to provide incentives for such persons to exert maximum efforts for the success of the Company. Common stock that may be issued under the ESPP will not exceed 47,794 shares, plus the number of shares of common stock that are automatically added on January 1st of each year for a period of ten years, commencing on January 1, 2015 and ending on January 1, 2024, in an amount equal to the lesser of (i) 0.8% of the total number of shares of outstanding common stock on December 31 of the preceding calendar year, and (ii) 29,411 shares of common stock. Similar to the 2014 Plan, the board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code. In the quarterly period ended March 31, 2016, the number of shares of common stock available for issuance under the ESPP was automatically increased by 29,411 shares pursuant to the terms of the ESPP and the Company issued 1,229 shares of common stock under the ESPP. During the quarterly period ended March 31, 2015, the number of shares of common stock available for issuance under the ESPP was automatically increased by 29,411 shares pursuant to the terms of the ESPP and the Company issued 15,107 shares of common stock under the ESPP. As of March 31, 2016 , there were 78,465 shares of common stock available for future issuance under the ESPP. Compensation Cost The compensation cost that has been charged against income for stock awards under the 2009 Stock Option Plan, the 2014 Plan, the 2015 Plan, and the ESPP was $274 and $296 for the three months ended March 31, 2016 and 2015. The total income tax benefit recognized in the statements of operations for share-based compensation arrangements was $0 for the three months ended March 31, 2016 and 2015 . Cash received from options exercised was $0 for both the three months ended March 31, 2016 , and 2015. Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations: Three Months Ended March 31, 2016 2015 Research and development $ 70 $ 52 Selling, general and administrative 204 211 Discontinued operations (Note 11) — 33 Total $ 274 $ 296

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period, pursuant to the policy described in Note 2. This determination requires significant judgments to be made. The following table summarizes the conclusions reached as of March 31, 2016 and December 31, 2015 for financial instruments measured at fair value on a recurring basis: Fair Value Hierarchy Classification Balance Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2015 Cash on deposit $ 46,935 $ 46,935 — — Money market funds 50 50 — — Total assets $ 46,985 $ 46,985 — — March 31, 2016 Cash on deposit $ 17,217 $ 17,217 — — Money market funds 20,799 20,799 — — Total assets $ 38,016 $ 38,016 — —

Accrued Severance and Retention

Accrued Severance and Retention Costs	3 Months Ended
	Mar. 31, 2016
Restructuring and Related Activities [Abstract]
Accrued Severance and Retention Costs	Accrued Severance and Retention Costs Compensatory Plan with Services Business Employees In connection with the Company's sale of its Services Business in July 2015 to Accuratus, which is more fully described in Note 11, the Company designed a compensatory plan to promote the retention of services of its non-executive employees supporting that business (the "Services Business Plan") as well to provide severance payments for non-executive employees that were not offered a comparable position by Accuratus (the "June 2015 Terminated Employees"). The Services Business Plan met the definition of an exit and disposal activity pursuant to FASB ASC 420-- Exit and Disposal Cost Obligations and the related retention and severance expense was recognized in 2015. As of March 31, 2016, the remaining severance and retention obligation for the June 2015 Terminated Employees was $184 . Compensatory Arrangement with Employees of the Company's Continuing Operations In connection with the Company's planned relocation of its continuing operations to Jersey City, New Jersey, the Company designed a compensatory plan to promote the retention of services of non-executive employees supporting its continuing operations (the "Retention Plan"). The Company has concluded that the Retention Plan meets the definition of an exit and disposal activity pursuant to FASB ASC 420-- Exit and Disposal Cost Obligations as of June 30, 2015, and all related expenses incurred were recognized in 2015. The Retention Plan provided that non-executive employees were eligible to receive cash bonuses, severance payments and related benefit premiums provided that such employees remained employed through December 31, 2015 and were not terminated for cause. During the year ended December 31, 2015, the Company recognized total expense of $1,012 , which was included in research and development and selling, general, and administrative expenses. As of March 31, 2016, the remaining obligation of $354 is included in accrued severance and retention liabilities in the accompanying balance sheet. Compensatory Arrangement with Former Executive Officer Yves J. Ribeill, Ph.D., resigned as President effective July 21, 2015. Dr. Ribeill resigned as a member of the board of directors effective March 16, 2016. The Company and Dr. Ribeill entered into an agreement, effective July 21, 2015, (the “Separation Agreement”), providing for certain payments and benefits to Dr. Ribeill over 12 months commencing with the first payroll period following the resignation date as President. The cash severance payments and related benefit premiums and payroll taxes totaled approximately $1,046 as of July 21, 2015, which was recognized as expense in the quarterly period ended September 30, 2015. As of March 31, 2016, the remaining obligation of $292 is included in accrued severance and retention liabilities in the accompanying balance sheet.

Sale of the Services Business,

Sale of the Services Business, Discontinued Operations	3 Months Ended
	Mar. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Sale of the Services Business, Discontinued Operations	Sale of the Services Business, Discontinued Operations On May 4, 2015, the Company's board of directors directed management to pursue a plan to sell the Service Business to Accuratus, representing a strategic shift in the Company's operations. The Company met the relevant criteria for reporting the service business as held for sale and in discontinued operations in the second quarter of 2015, pursuant to FASB Topic 205-20, Presentation of Financial Statements--Discontinued Operations , and FASB Topic 360, Property, Plant, and Equipment . The Company assessed the Services Business net asset group for impairment pursuant to FASB Topic 360 and recorded a $1,350 impairment charge on classification of property and equipment assets as held for sale in the quarterly period ended June 30, 2015. Sale of the Services Business On July 21, 2015, the Company completed the sale of the Services Business to Accuratus pursuant to the Purchase Agreement, with an effective date of July 17, 2015 for an aggregate purchase price of $3,875 , subject to a working capital adjustment of $824 , which reduced the proceeds at closing. In addition, a portion of the consideration payable at closing equal to $500 was withheld and is subject to an escrow for a period of 12 months from the date of closing to satisfy indemnification obligations of the Company in connection with breaches of any representation and warranties and other customary obligations under the terms of the Purchase Agreement. The Company has not identified any breaches or other events that would cause a reduction in the escrow funds expected to be received by the Company. The escrow funds were recorded as a receivable included in prepaid expenses and other current assets in the accompanying balance sheets. The net cash consideration received by the Company upon closing in July 2015 was $2,549 , after adjusting for the items described above and a nominal escrow fee. Continuing Involvement with Accuratus The Company and Accuratus entered into the Services Agreement pursuant to which Accuratus will provide the Company with certain contract research and development services for 18 months (the "Initial Term") following the closing of the sale of the Services Business for a minimum purchase obligation of at least $3,300 due from the Company over the Initial Term of the Services Agreement. The purpose of the Services Agreement is to replace services that were previously provided internally by employees of the Company prior to the sale of the Services Business. The employees performing these services became employees of Accuratus in connection with this sale transaction. In the quarterly period ended March 31, 2016, the Company recognized $1,177 of expense for services provided by Accuratus under the Services Agreement, which is included in research and development expense in the accompanying unaudited interim statements of operations. Discontinued Operations The following table presents revenue, (expenses), gains, and (losses) attributable to discontinued operations: Three months ended March 31, 2015 Major line items constituting loss of discontinued operations: Revenue $ 3,232 Cost of revenue (3,231 ) Research and development (431 ) Selling, general, and administrative (23 ) Loss from discontinued operations $ (453 ) The following table presents depreciation, capital expenditures, and significant operating and investing non-cash items related to the discontinued operations: Three months ended March 31, 2015 Depreciation expense $ 282 Purchases of property and equipment (171 ) Stock-based compensation 33 Changes in deferred rent (57 ) Equipment purchases in accounts payable and accrued expenses 25

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Termination of Sales Agreement On April 10, 2016, SCYNEXIS terminated that certain sales agreement by and between the Company and Cowen, dated November 11, 2015 (the “Agreement”). The Agreement was terminable at will by the Company upon giving ten days written notice to Cowen. The Agreement previously established an ATM offering program through which the Company had the right to sell, from time to time, through Cowen, as the Company’s agent, up to an aggregate of $40,000 of the Company’s common stock. The Company sold no shares of common stock under the Agreement. Entry into Sales Agreement On April 11, 2016, the Company entered into the Sales Agreement with Cantor pursuant to which the Company may sell from time to time, at its option, up to an aggregate of $40,000 of the Company’s common stock, through Cantor, as sales agent. Pursuant to the Sales Agreement, sales of the common stock, if any, will be made under the Company’s previously filed and currently effective registration statement on Form S-3 (File No. 333-207705), at market prices by any method that is deemed to be an “at-the-market” offering as defined in Rule 415 under the Securities Act, as amended (the “Securities Act”), including sales made directly on the NASDAQ Global Market and any other trading market for the common stock, and sales to or through a market maker other than on an exchange.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit with a bank, which exceeds the FDIC insurance limits, as well as accounts receivable. Ongoing credit evaluations of the bank and customers' financial condition and independent ratings are reviewed by the Company. Collateralization of deposits has not been required.
Other Assets	Other Assets Other assets consist primarily of the refundable long-term deposit on the leased building facility and the restricted cash posted as collateral for the Company's corporate credit card program.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs are expenses directly related to the Form S-3 filed with the SEC on October 30, 2015 and declared effective on November 16, 2015 (the "Shelf Registration"). These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized, including fees incurred by the independent registered public accounting firm directly related to the Shelf Registration. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis in the event the Company completes an offering under the Shelf Registration, with any remaining deferred offering costs charged to the results of operations at the end of the three-year life of the Shelf Registration.
Revenue Recognition and Deferred Revenue	Revenue Recognition and Deferred Revenue The Company has entered into collaboration arrangements in exchange for non-refundable upfront payments and consideration as services are performed. These arrangements include multiple elements, such as the sale of licenses and the provision of services. Under these arrangements, the Company also is entitled to receive development milestone payments and royalties in the form of a designated percentage of product sales. The Company classifies non-refundable upfront payments, milestone payments and royalties received under collaboration and licensing agreements as revenues within its statements of operations because the Company views such activities as being central to its business operations. Revenue is recognized when all of the following conditions are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) fees are fixed or determinable, and (iv) collection of fees is reasonably assured. When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in ASC subtopic 605-25, Multiple-Element Arrangements . If the Company determines that an arrangement includes multiple elements, it determines whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting. An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s arrangements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered. Non-refundable upfront license fees are recorded as deferred revenue and recognized into revenue on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, the Company recognizes non-refundable upfront fees into revenue through the date the deliverable is satisfied. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. In arrangements that include license rights and other non-contingent deliverables, such as participation in a steering committee, these deliverables do not have standalone value because the non-contingent deliverables are dependent on the license rights. That is, the non-contingent deliverables would not have value without the license rights, and only the Company can perform the related services. Upfront license rights and non-contingent deliverables, such as participation in a steering committee, do not have standalone value as they are not sold separately and they cannot be resold. In addition, when non-contingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate earnings process. As such, the Company accounts for the license and the non-contingent deliverables as a single combined unit of accounting. In such instances, the license revenue in the form of non-refundable upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes contingent event-based payments under license agreements when the payments are received. The Company has not received any royalty payments to date. The Company will recognize a milestone payment when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it: 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement. Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets. The Company’s deferred revenue includes non-refundable upfront payments received under certain licensing and collaboration arrangements that contain substantive performance obligations that the Company is providing over respective defined service or estimated relationship periods. Such non-refundable upfront payments are recognized over these defined service or estimated relationship periods.
Collaboration Arrangements	Collaboration Arrangements The Company assesses its contractual arrangements, and presents costs incurred and payments received under contractual arrangements, in accordance with ASC 808, Collaborative Arrangements ("Topic 808"), when the Company determines that the contractual arrangement includes a joint operating activity, has active participation by both parties, and both parties are subject to significant risks and rewards under the arrangement. When reimbursement payments are due to the Company under a collaborative arrangement within the scope of Topic 808, the Company determines the appropriate classification for each specific reimbursement payment in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement. The Company's August 2013 development, license, and supply agreement with R-Pharm, CJSC (“R-Pharm”), combined with the supplemental arrangement in November 2014, is a collaborative arrangement pursuant to Topic 808 and the Company’s previously described accounting policy. The reimbursements due from R-Pharm for specified research and development costs incurred by the Company are classified as a reduction to research and development expense in the accompanying statements of operations. The reimbursements due to the Company are recorded as a reduction of expense when (i) the reimbursable expenses have been incurred by the Company, (ii) persuasive evidence of a cost reimbursement arrangement exists, (iii) reimbursable costs are fixed or determinable, and (iv) the collection of the reimbursement payment is reasonably assured.
Research and Development	Research and Development Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance. The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting SCY-078 clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel. Reimbursements of certain research and development costs by parties under collaborative arrangements have been recorded as a reduction of research and development expense presented within the statement of operations.
Patent Expense	Patent Expenses Costs related to filing and pursuing patent applications, as well as costs related to maintaining the Company's existing patent portfolio, are recorded as expense as incurred since recoverability of such expenditures is uncertain.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability.The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows: • Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; • Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and • Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.
Income Taxes	Income Taxes The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions. Certain modifications made to an outstanding incentive stock option award at any time after the initial grant dates which are considered to be “material modifications”, as defined within the Internal Revenue Code, may result in the affected award being recharacterized as a non-statutory stock option. The effects of any recharacterization modification for purposes of income tax accounting are recognized on a prospective basis.
Share-based Compensation	Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date. The Company values equity instruments and stock options granted to employees and non-employee directors using the Black-Scholes valuation model. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods.
Basic and Diluted Net Loss per Share of Common Stock	Basic and Diluted Net Loss per Share of Common Stock The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share ("Topic 260”). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period.
Effect of Recent Accounting Pronouncements	Effect of Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606, or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In applying the new revenue recognition model to contracts with customers, an entity: (1) identifies the contract(s) with a customer; (2) identifies the performance obligations in the contract(s); (3) determines the transaction price; (4) allocates the transaction price to the performance obligations in the contract(s); and (5) recognizes revenue when (or as) the entity satisfies a performance obligation. The accounting standards update applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification. The accounting standards update also requires significantly expanded quantitative and qualitative disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the Company’s financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is not early adopting ASU 2014-15. The Company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the Company’s financial statements, and the actual impact will be dependent upon the Company’s liquidity and the nature or significance of future events or conditions that exist upon adopting the updated standard. In February 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-02, Leases , or ASU 2016-02. The new guidance requires lessees to recognize the assets and liabilities arising from leases on the balance sheet. For public companies, ASU 2016-02 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2018, and early adoption is permitted. The Company is currently evaluating the impact that the implementation of ASU 2016-02 will have on the Company’s financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation , or ASU 2016-09. The new guidance is an update to ASC 718 and simplifies several aspects of the accounting for share-based transactions. For public companies, ASU 2016-09 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016. The Company is currently evaluating the impact that the implementation of ASU 2016-09 will have on the Company’s financial statements. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers , or ASU 2016-10. The new guidance is an update to ASC 606 and provides clarity on: identifying performance obligations and licensing implementation. For public companies, ASU 2016-10 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016. The Company is currently evaluating the impact that the implementation of ASU 2016-10 will have on the Company’s financial statements.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Research and Development Expenses and Reimbursements Due	Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the three months ended March 31, 2016 and 2015, is presented as follows: Three months ended March 31, 2016 2015 Research and development expense, gross $ 4,962 $ 3,981 Less: Reimbursement of research and development expense 219 194 Research and development expense, net of reimbursements $ 4,743 $ 3,787
Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding	The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive. Three Months Ended March 31, 2016 2015 Warrants to purchase Series C-1 Preferred 14,033 14,033 Stock options 1,450,453 575,416

Prepaid Expenses and Other Cu20

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	March 31, 2016 December 31, 2015 Prepaid SCY-078 development services $ 513 $ 108 Prepaid insurance 99 285 Other prepaid expenses 145 91 Other receivable due from R-Pharm 648 430 Escrow receivable due from Accuratus (Note 11) 500 500 Other current assets — 38 Total prepaid expenses and other current assets $ 1,905 $ 1,452

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2016
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	March 31, 2016 December 31, 2015 Accrued research and development expenses $ 1,950 $ 1,903 Accrued employee bonus compensation 215 776 Employee withholdings 25 42 Other accrued expenses 384 428 Total accrued expenses $ 2,574 $ 3,149

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments	Future minimum lease payments for all operating leases as of March 31, 2016 are as follows: March 31, 2016 to December 31, 2016 $ 224 2017 307 2018 182 2019 — 2020 — Thereafter — Total $ 713

Common Stock (Tables)

Common Stock (Tables)	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Summary of Common Stock Shares Activity	The following table summarizes common stock share activity for the three months ended March 31, 2016 : Shares of Common Stock Additional Paid-in Capital Accumulated Deficit Total Stockholders' Equity Balance, December 31, 2015 13,905,599 $ 14 $ 192,069 $ (150,134 ) $ 41,949 Net loss — — — (7,184 ) (7,184 ) Stock-based compensation expense — — 274 — 274 Common stock issued through employee stock purchase plan 1,229 — 5 — 5 Balance, March 31, 2016 13,906,828 $ 14 $ 192,348 $ (157,318 ) $ 35,044
Common Stock Reserved For Future Issuances	The Company had reserved shares of common stock for future issuance as follows: March 31, December 31, Outstanding stock options 1,450,453 1,379,727 Outstanding Series C-1 Preferred warrants 14,033 14,033 For possible future issuance under 2014 Equity Incentive Plan (Note 8) 1,037,822 552,415 For possible future issuance under Employee Stock Purchase Plan (Note 8) 78,465 50,283 For possible future issuance under 2015 Inducement Plan (Note 8) 165,000 165,000 Total common shares reserved for future issuance 2,745,773 2,161,458

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation Expense Related to Stock Options	Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations: Three Months Ended March 31, 2016 2015 Research and development $ 70 $ 52 Selling, general and administrative 204 211 Discontinued operations (Note 11) — 33 Total $ 274 $ 296

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Summary of Financial Instruments Measured on a Recurring Basis	The following table summarizes the conclusions reached as of March 31, 2016 and December 31, 2015 for financial instruments measured at fair value on a recurring basis: Fair Value Hierarchy Classification Balance Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2015 Cash on deposit $ 46,935 $ 46,935 — — Money market funds 50 50 — — Total assets $ 46,985 $ 46,985 — — March 31, 2016 Cash on deposit $ 17,217 $ 17,217 — — Money market funds 20,799 20,799 — — Total assets $ 38,016 $ 38,016 — —

Sale of the Services Business26

Sale of the Services Business, Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations Financial Statement Impact	The following table presents revenue, (expenses), gains, and (losses) attributable to discontinued operations: Three months ended March 31, 2015 Major line items constituting loss of discontinued operations: Revenue $ 3,232 Cost of revenue (3,231 ) Research and development (431 ) Selling, general, and administrative (23 ) Loss from discontinued operations $ (453 ) The following table presents depreciation, capital expenditures, and significant operating and investing non-cash items related to the discontinued operations: Three months ended March 31, 2015 Depreciation expense $ 282 Purchases of property and equipment (171 ) Stock-based compensation 33 Changes in deferred rent (57 ) Equipment purchases in accounts payable and accrued expenses 25

Description of Business and B27

Description of Business and Basis of Preparation - Additional Information (Detail) - USD ($)	Apr. 11, 2016	Apr. 10, 2016	Nov. 16, 2015	Nov. 11, 2015	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Formation date					Nov. 4, 1999
Common Stock [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Shelf registration maximum equity offering price			$ 150,000,000
Common Stock [Member] | Sales Agreement Prospectus [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Shelf registration maximum equity offering price			$ 40,000,000	$ 40,000,000
Common Stock [Member] | Sales Agreement Prospectus [Member] | Subsequent Event [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Shelf registration maximum equity offering price	$ 40,000,000	$ 40,000,000

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Aug. 31, 2013	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Subsidiary, Sale of Stock [Line Items]
Deferred offering costs		$ 331,000		$ 417,000
Royalty payments received		0
Upfront payment received	$ 1,500,000
Deferred revenue recognition period	70 months
Revenue recognized from upfront payments		64,000	$ 65,000
Other receivable due from R-Pharm		648,000		$ 430,000
Sales Agreement Prospectus [Member]
Subsidiary, Sale of Stock [Line Items]
Deferred offering costs		$ 111,000

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Schedule of Research and Development Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Accounting Policies [Abstract]
Research and development expense, gross	$ 4,962	$ 3,981
Less: Reimbursement of research and development expense	219	194
Research and development expense, net of reimbursements	$ 4,743	$ 3,787

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Shares (Details) - shares	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Series C-1 Preferred warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	14,033	14,033
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	1,450,453	575,416

Prepaid Expenses and Other Cu31

Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid SCY-078 development services	$ 513	$ 108
Prepaid insurance	99	285
Other prepaid expenses	145	91
Other receivable due from R-Pharm	648	430
Consideration in escrow	500	500
Other current assets	0	38
Total prepaid expenses and other current assets	$ 1,905	$ 1,452

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Accrued research and development expenses	$ 1,950	$ 1,903
Accrued employee bonus compensation	215	776
Employee withholdings	25	42
Other accrued expenses	384	428
Total accrued expenses	$ 2,574	$ 3,149

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Jul. 22, 2015USD ($)ft²	Mar. 31, 2016USD ($)Agreement
Commitment And Contingencies [Line Items]
Number of additional license agreements | Agreement		2
License agreements fee		$ 2,300,000
Maximum [Member]
Commitment And Contingencies [Line Items]
Milestone payments from the Company		19,000,000
Jersey City, New Jersey [Member]
Commitment And Contingencies [Line Items]
Area of subleased space (in sqft) | ft²	10,141
Base rent, per month	$ 25,000
Annual increase in base rent (percent)	3.00%
Security deposit paid	$ 74,000
Rent expense		$ 74,000

Commitments and Contingencies34

Commitments and Contingencies - Future Minimum Lease Payments (Detail) $ in Thousands	Mar. 31, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
Mach 31, 2016 to December 31, 2016	$ 224
2,017	307
2,018	182
2,019	0
2,020	0
Thereafter	0
Total	$ 713

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended
	Jul. 31, 2006	Mar. 31, 2016	Dec. 31, 2015
Schedule of Capitalization, Equity [Line Items]
Common stock, par value (in dollars per share)		$ 0.001	$ 0.001
Common stock, shares authorized (in shares)		125,000,000	125,000,000
Common stock, shares issued (in shares)		13,906,828	13,905,599
Common stock, shares outstanding (in shares)		13,906,828	13,905,599
Number of warrants issued to purchase common stock		14,033	14,033
Series C-1 Convertible Preferred Stock [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock	196,923
Exercise price of warrants	$ 3.25
Fair value of warrants	$ 459
Common Stock [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock	14,033
Exercise price of warrants	$ 45.61

Common Stock - Summary of Commo

Common Stock - Summary of Common Stock Shares Activity (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance (in shares)	13,905,599
Beginning balance	$ 41,949
Net loss	(7,184)	$ (6,384)
Stock-based compensation expense	274
Common stock issued through employee stock purchase plan	$ 5
Ending balance (in shares)	13,906,828
Ending balance	$ 35,044
Common Stock [Member]
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance (in shares)	13,905,599
Beginning balance	$ 14
Common stock issued through employee stock purchase plan (in shares)	1,229
Ending balance (in shares)	13,906,828
Ending balance	$ 14
Additional Paid-in Capital [Member]
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance	192,069
Stock-based compensation expense	274
Common stock issued through employee stock purchase plan	5
Ending balance	192,348
Retained Earnings [Member]
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance	(150,134)
Net loss	(7,184)
Ending balance	$ (157,318)

Common Stock - Schedule of Rese

Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) - shares	Mar. 31, 2016	Jan. 01, 2016	Dec. 31, 2015	Jan. 01, 2015
Class of Stock [Line Items]
Outstanding stock options	1,450,453		1,379,727
Outstanding Series C-1 Preferred warrants	14,033		14,033
Total common shares reserved for future issuance	2,745,773		2,161,458
2014 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Possible future issuance under equity compensation plan (shares)	1,037,822	556,223	552,415	340,484
2014 Employee Stock Purchase Plan [Member]
Class of Stock [Line Items]
Possible future issuance under equity compensation plan (shares)	78,465		50,283
2015 Inducement Plan [Member]
Class of Stock [Line Items]
Possible future issuance under equity compensation plan (shares)	165,000		165,000

Stock-based Compensation - 200

Stock-based Compensation - 2009 Stock Option Plan (Details) - 2009 Stock Option Plan [Member]	3 Months Ended
	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of options	10 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of exercise price	100.00%
Vesting period of options	3 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of exercise price	110.00%
Vesting period of options	4 years

Stock-based Compensation - 201

Stock-based Compensation - 2014 Equity Incentive Plan (Details) - shares	May. 02, 2014	Mar. 31, 2016	Jan. 01, 2016	Dec. 31, 2015	Jan. 01, 2015
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effective date of equity incentive plan	May 2, 2014
Common stock outstanding percentage	4.00%
Number of shares of common stock for future issuance, board of directors prerogative, increase in period (shares)	0
Possible future issuance under equity compensation plan (shares)		1,037,822	556,223	552,415	340,484
Options granted in period (shares)		86,795
2014 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Base number of new shares available for future issuance under equity incentive plan	1,122,731
Common stock issuable period	10 years
2009 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional awards expected to be granted	0

Stock-based Compensation - 240

Stock-based Compensation - 2015 Inducement Plan (Details) - 2015 Inducement Plan [Member] - shares	Mar. 31, 2016	Dec. 31, 2015	Mar. 26, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under the plan			450,000
Possible future issuance under equity compensation plan (shares)	165,000	165,000

Stock-based Compensation - 241

Stock-based Compensation - 2014 Employee Stock Purchase Plan (Details) - 2014 Employee Stock Purchase Plan [Member] - shares	May. 02, 2014	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effective date of employee stock purchase plan	May 2, 2014
For possible future issuance under employee stock purchase plan	47,794
Common stock issuable period	10 years
Common stock outstanding percentage	0.80%
Employee stock purchase plan, number of shares, which might be added to common stock outstanding (shares)	29,411
Number of shares of common stock for future issuance, board of directors prerogative, increase in period (shares)	0
Aggregate number of shares of the Company's common stock that may be issued (shares)		29,411	29,411
Common stock issued through employee stock purchase plan (in shares)		1,229	15,107
Possible future issuance under equity compensation plan (shares)		78,465		50,283

Stock-based Compensation - Com

Stock-based Compensation - Compensation Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation	$ 274	$ 296
Tax benefit from compensation expense	0	0
Cash received from option exercised	$ 0	$ 0

Stock-based Compensation - Expe

Stock-based Compensation - Expense Related to Stock Options (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	$ 274	$ 296
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	70	52
Selling, general and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	204	211
Discontinued operations [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	$ 0	$ 33

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial instruments	$ 38,016	$ 46,985
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial instruments	38,016	46,985
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial instruments	0	0
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial instruments	0	0
Interest-bearing Deposits [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial instruments	17,217	46,935
Interest-bearing Deposits [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial instruments	17,217	46,935
Interest-bearing Deposits [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial instruments	0	0
Interest-bearing Deposits [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial instruments	0	0
Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial instruments	20,799	50
Money Market Funds [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial instruments	20,799	50
Money Market Funds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial instruments	0	0
Money Market Funds [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial instruments	$ 0	$ 0

Accrued Severance and Retenti45

Accrued Severance and Retention Costs (Details) - USD ($) $ in Thousands	Jul. 21, 2015	Dec. 31, 2015	Mar. 31, 2016
Restructuring Cost and Reserve [Line Items]
Accrued severance and retention costs, current portion		$ 2,639	$ 830
President [Member]
Restructuring Cost and Reserve [Line Items]
Accrued severance and retention costs, current portion	$ 1,046		292
Severance payment period	12 months
Employee Severance [Member] | Retention Plan [Member]
Restructuring Cost and Reserve [Line Items]
Accrued severance and retention costs, current portion			354
Employee Severance [Member] | Research and Development, and Selling, General, and Administrative Expense | Retention Plan [Member]
Restructuring Cost and Reserve [Line Items]
Research and development and selling, general and administrative expense		$ 1,012
Discontinued Operations, Disposed of by Sale [Member] | Services Business [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Remaining severance and retention costs			$ 184

Sale of the Services Business46

Sale of the Services Business, Discontinued Operations - Additional Information (Details) - USD ($) $ in Thousands	Jul. 21, 2015	Mar. 31, 2016	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration in escrow		$ 500			$ 500
Research and development, net		4,743		$ 3,787
Continuing Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Research and development, net		$ 1,177
Research and Development Arrangement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Services agreement, term		18 months
Minimum purchase obligation		$ 3,300
Discontinued Operations, Held-for-sale [Member] | Nonrecurring Adjustment [Member] | Services Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charge from classification of assets as held for sale			$ 1,350
Discontinued Operations, Disposed of by Sale [Member] | Services Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale of Services Business, aggregate purchase price	$ 3,875
Working capital adjustment	824
Consideration in escrow	$ 500
Consideration payable held in escrow, period	12 months
Net cash consideration received at closing	$ 2,549

Sale of the Services Business47

Sale of the Services Business, Discontinued Operations - Revenue, Expense, Gain, and Losses Attributable to Discontinued Operations (Details) - Services Business [Member] - Discontinued Operations, Disposed of by Sale [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2015USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	$ 3,232
Cost of revenue	(3,231)
Research and development	(431)
Selling, general, and administrative	(23)
Loss from discontinued operations	$ (453)

Sale of the Services Business48

Sale of the Services Business, Discontinued Operations - Depreciation, Capital Expenditures, and Significant Operating and Investing Non-Cash Items Related to Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Stock-based compensation	$ 274	$ 296
Changes in deferred rent	$ 0	(57)
Services Business [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation expense		282
Purchases of property and equipment		(171)
Stock-based compensation		33
Changes in deferred rent		(57)
Equipment purchases in accounts payable and accrued expenses		$ 25

Subsequent Events (Details)

Subsequent Events (Details) - Common Stock [Member] - USD ($)	Apr. 11, 2016	Apr. 10, 2016	Nov. 16, 2015	Nov. 11, 2015
Subsequent Event [Line Items]
Shelf registration maximum equity offering price			$ 150,000,000
Sales Agreement Prospectus [Member]
Subsequent Event [Line Items]
Shelf registration maximum equity offering price			$ 40,000,000	$ 40,000,000
Sales Agreement Prospectus [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Shelf registration maximum equity offering price	$ 40,000,000	$ 40,000,000